• Peng-Lei Yang, Jiang-Quan Yu, and Han-Bing Chen.
• Graduate school of Dalian Medical University, Dalian, Liaoning province, China; Department of Critical Care Medicine, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu Province, China. Electronic address: yangpengleichina@outlook.com.
• Heart Lung. 2021 Mar 1; 50 (2): 252-261.

BackgroundThe evidence for the safety of high-flow nasal cannula (HFNC) in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients is conflicting.ObjectivesTo evaluate the intubation and mortality risks of HFNC compared to non-invasive ventilation (NIV) and conventional oxygen therapy (COT) for AECOPD patients.MethodsA search of electronic databases was performed. Studies that used HFNC to treat AECOPD patients were identified.ResultsSeven RCTs and one observational study were included. There were no differences in intubation risk (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.49 to 1.78, p = 0.84, very low certainty) and mortality risk (RR 0.91, 95% CI 0.46 to 1.79, p = 0.77, very low certainty) for HFNC compared with NIV. No data were available for intubation or mortality risk for HFNC compared with COT.ConclusionFor AECOPD patients, low-quality evidence indicates that HFNC does not increase intubation and mortality risks compared to NIV.Copyright © 2020 Elsevier Inc. All rights reserved.

14 keywords...

hide…